AU2001259215A1 - Human anti-cd40 antibodies and methods of making and using same - Google Patents
Human anti-cd40 antibodies and methods of making and using sameInfo
- Publication number
- AU2001259215A1 AU2001259215A1 AU2001259215A AU5921501A AU2001259215A1 AU 2001259215 A1 AU2001259215 A1 AU 2001259215A1 AU 2001259215 A AU2001259215 A AU 2001259215A AU 5921501 A AU5921501 A AU 5921501A AU 2001259215 A1 AU2001259215 A1 AU 2001259215A1
- Authority
- AU
- Australia
- Prior art keywords
- antibodies
- making
- methods
- same
- human anti
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20060100P | 2000-04-28 | 2000-04-28 | |
US60200601 | 2000-04-28 | ||
PCT/US2001/013672 WO2001083755A2 (en) | 2000-04-28 | 2001-04-27 | Human anti-cd40 antibodies and methods of making and using same |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001259215A1 true AU2001259215A1 (en) | 2001-11-12 |
Family
ID=22742393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001259215A Abandoned AU2001259215A1 (en) | 2000-04-28 | 2001-04-27 | Human anti-cd40 antibodies and methods of making and using same |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2001259215A1 (en) |
TW (1) | TWI264467B (en) |
WO (1) | WO2001083755A2 (en) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
US20030059427A1 (en) * | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
DE60143535D1 (en) * | 2000-10-02 | 2011-01-05 | Novartis Vaccines & Diagnostic | HUMAN ANTIBODIES AGAINST CD40 |
MXPA03003919A (en) * | 2000-11-03 | 2003-09-25 | Univ South Florida | Methods and compositions for stimulating cd45 and thereby suppressing microglial activation associated with alzheimer s disease. |
CA2658221C (en) | 2001-04-27 | 2012-11-27 | Kyowa Hakko Kirin Co., Ltd. | Anti-cd40 monoclonal antibody |
WO2003029296A1 (en) * | 2001-10-02 | 2003-04-10 | Chiron Corporation | Human anti-cd40 antibodies |
WO2003028809A1 (en) * | 2001-10-02 | 2003-04-10 | Chiron Corporation | Methods of therapy for b-cell malignancies |
AR039067A1 (en) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | ANTIBODIES FOR CD40 |
WO2003045978A2 (en) * | 2001-11-26 | 2003-06-05 | Chiron Corporation | Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment |
EP2075256A2 (en) | 2002-01-14 | 2009-07-01 | William Herman | Multispecific binding molecules |
EP1694360B1 (en) * | 2003-11-04 | 2010-08-04 | Novartis Vaccines and Diagnostics, Inc. | Use of antagonist anti-cd40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection |
EP2236172A1 (en) * | 2003-11-04 | 2010-10-06 | Novartis Vaccines and Diagnostics, Inc. | Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers |
ES2346978T3 (en) | 2003-11-04 | 2010-10-22 | Novartis Vaccines And Diagnostics, Inc. | USE OF ANTI-CD40 ANTIGONIST MONOCLONANT ANTIBODIES FOR THE TREATMENT OF MULTIPLE MYELOMA. |
US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
WO2005044304A2 (en) * | 2003-11-04 | 2005-05-19 | Chiron Corporation | Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia |
WO2006073443A2 (en) * | 2004-04-27 | 2006-07-13 | Novartis Vaccines And Diagnostics, Inc. | Antagonist anti-cd40 monoclonal antibodies and methods for their use |
CN101325970B (en) | 2005-11-01 | 2013-08-14 | 诺华有限公司 | Uses of anti-cd40 antibodies |
EA018301B1 (en) | 2006-04-21 | 2013-07-30 | Новартис Аг | Pharmaceutical compositions comprising antagonist monoclonal anti-cd40 antibody and use thereof |
CN101910414B (en) | 2007-11-07 | 2016-01-13 | 健泰科生物技术公司 | For assessment of the method and composition of the responsiveness of B cell lymphoma antagonism CD40 Antybody therapy |
WO2010104747A2 (en) | 2009-03-10 | 2010-09-16 | Baylor Research Institute | Antigen presenting cell targeted vaccines |
AU2010222928B2 (en) | 2008-07-16 | 2012-11-29 | Baylor Research Institute | Antigen presenting cell targeted vaccines |
JP2012511014A (en) * | 2008-12-05 | 2012-05-17 | エイエルエス・セラピー・デベロップメント・インスティテュート | Methods for treating neurodegenerative diseases |
US9044459B2 (en) | 2008-12-05 | 2015-06-02 | Als Therapy Development Institute | Method for the treatment of neurodegenerative diseases |
DK2406286T3 (en) | 2009-03-10 | 2016-08-22 | Baylor Res Inst | Anti-cd40 antibodies and uses thereof |
MX2011010938A (en) | 2009-04-18 | 2012-01-12 | Genentech Inc | Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies. |
AR083847A1 (en) | 2010-11-15 | 2013-03-27 | Novartis Ag | FC VARIANTS (CONSTANT FRAGMENT) SILENCERS OF ANTI-CD40 ANTIBODIES |
WO2012135132A1 (en) | 2011-03-25 | 2012-10-04 | Baylor Research Institute | Compositions and methods to immunize against hepatitis c virus |
GB201115280D0 (en) * | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
GB201322583D0 (en) * | 2013-12-19 | 2014-02-05 | Alligator Bioscience Ab | Antibodies |
JP7037884B2 (en) | 2014-01-13 | 2022-03-17 | ベイラー リサーチ インスティテュート | New vaccines for HPV and HPV-related diseases |
JP6654187B2 (en) | 2014-08-12 | 2020-02-26 | アリゲーター・バイオサイエンス・アーベー | Combination therapy using anti-CD40 antibody |
MA41459A (en) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L ILLNESSES OR DISORDERS |
EP3355921A4 (en) | 2015-09-30 | 2019-05-22 | Janssen Biotech, Inc. | Antagonistic antibodies specifically binding human cd40 and methods of use |
MA45488A (en) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | CELL CULTURE PROCESSES, KITS AND APPARATUS |
BR112018008891A8 (en) | 2015-11-03 | 2019-02-26 | Janssen Biotech Inc | antibodies that specifically bind to pd-1 and tim-3 and their uses |
JP7461741B2 (en) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | Anti-PD-L1 and IL-2 Cytokines |
AU2017308734A1 (en) | 2016-08-12 | 2019-02-14 | Janssen Biotech, Inc. | Fc engineered anti-TNFR superfamily member antibodies having enhanced agonistic activity and methods of using them |
SG11201900746RA (en) | 2016-08-12 | 2019-02-27 | Janssen Biotech Inc | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions |
KR102606210B1 (en) | 2017-04-27 | 2023-11-24 | 주노 테라퓨틱스 게엠베하 | Oligomeric particle reagents and methods of use thereof |
WO2018217918A2 (en) | 2017-05-24 | 2018-11-29 | Als Therapy Development Institute | Therapeutic anti-cd40 ligand antibodies |
KR102198998B1 (en) * | 2017-06-01 | 2021-01-07 | 서울대학교 산학협력단 | Novel anti-cd40 antibodies and uses thereof |
US10610585B2 (en) | 2017-09-26 | 2020-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating and preventing HIV |
US11672826B2 (en) | 2018-08-30 | 2023-06-13 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
CN113365663A (en) | 2018-08-30 | 2021-09-07 | Hcw生物科技公司 | Single-chain chimeric polypeptides and uses thereof |
WO2020047299A1 (en) | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
CN109678959B (en) * | 2019-02-22 | 2020-12-08 | 北京免疫方舟医药科技有限公司 | anti-CD 40 antibodies and uses thereof |
CN114269903A (en) | 2019-06-21 | 2022-04-01 | Hcw生物科技公司 | Multi-chain chimeric polypeptides and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0945465T3 (en) * | 1992-07-09 | 2007-01-15 | Novartis Vaccines & Diagnostic | Antagonistic monoclonal antibodies to human CD40 |
ES2211884T3 (en) * | 1993-10-01 | 2004-07-16 | Immunex Corporation | ANTIBODIES AGAINST CD40. |
CA2219361C (en) * | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP0823941A4 (en) * | 1995-04-28 | 2001-09-19 | Abgenix Inc | Human antibodies derived from immunized xenomice |
WO2000000156A2 (en) * | 1998-06-26 | 2000-01-06 | Trustees Of Dartmouth College | Methods for modulating immunological responses by targeting antigen to apcs in conjuction with anti-cd40 ligands |
-
2001
- 2001-04-27 WO PCT/US2001/013672 patent/WO2001083755A2/en active Application Filing
- 2001-04-27 AU AU2001259215A patent/AU2001259215A1/en not_active Abandoned
- 2001-04-30 TW TW090110333A patent/TWI264467B/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2001083755A2 (en) | 2001-11-08 |
WO2001083755A3 (en) | 2002-05-23 |
TWI264467B (en) | 2006-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001259215A1 (en) | Human anti-cd40 antibodies and methods of making and using same | |
AU2001261160A1 (en) | Prosthesis and method of making | |
AU2002230831A1 (en) | Compositions of human proteins and method of use thereof | |
ZA200305825B (en) | Modified antibodies and methods of use | |
AU2002320058A1 (en) | Magnetic-nanoparticle conjugates and methods of use | |
AU2002320456A1 (en) | Removable stent and method of using the same | |
IL206980A0 (en) | Antibodies that bind human interleukin-18 and methods of making and using | |
AU2001270943A1 (en) | Surgical instrument and method of using the same | |
WO2002030986A3 (en) | HUMANIZED ANTI-LT-β-R ANTIBODIES | |
AU2001256325A1 (en) | Human and humanized fap-alpha-specific antibodies | |
AU2002314466A1 (en) | Withasol and methods of use | |
AU2001251358A1 (en) | Prion-binding ligands and methods of using same | |
AU2002225954A1 (en) | Dipeptidylpeptidases and methods of use | |
AU2001272840A1 (en) | Adjustable chair and method of use | |
AU2002340167A1 (en) | Anti-hla-dr antibodies and the methods of using thereof | |
AU2002324965A1 (en) | Artificial kidney and methods of using same | |
AU2002326751A1 (en) | Immunoglobulin e vaccines and methods of use thereof | |
AU7676300A (en) | Human anti-adipocyte monoclonal antibodies and their use | |
AU2002211183A1 (en) | Prosthetic construct and methods for its manufacture and use | |
AU2001260774A1 (en) | Bio-support and preparing method of the same | |
AU2002213346A1 (en) | Osteopontin-coated surfaces and methods of use | |
HK1046646A1 (en) | Preparations and method of producing the same | |
AU2002363938A1 (en) | Methods and use of motoneuronotropic factors | |
AU2001261375A1 (en) | Human caspase-12 materials and methods | |
AU2002310237A1 (en) | Sponge-derived terpenoids and methods of use |